FDA approves RHA Redensity Eye for undereye hollowing

On August 20, 2026, the FDA approved RHA Redensity Eye for correcting moderate to severe undereye hollowing in adults aged 22 or older, giving clinics a cleared option for a highly sensitive zone. This hyaluronic acid gel from Teoxane and Revance is formulated with Preserved Network Technology and includes mepivacaine for comfort. Because periorbital filling is technically demanding, having an approved product for infraorbital hollows helps mitigate some of the safety concerns injectors face when working off-label. The approval is backed by a 52-week U.S. pivotal study showing that 93 percent of patients had aesthetic improvement at three months, with results lasting up to 12 months without touch-ups. Practically, this launch targets a primary driver of current patient consultations. The rise of GLP-1 therapies has left a growing cohort of patients with rapid facial fat loss, which often manifests as a hollow, fatigued undereye appearance. Adding this approved filler to your inventory allows you to market a predictable, long-lasting solution specifically to these patients.

Source: MedEsthetics Magazine, https://www.medestheticsmag.com/news/revance-and-teoxane-announce-the-fda-approval-of-rha-redensity-eye-for-undereye-hollowing